Delivering efficient liver-directed AAV-mediated gene therapy

Gene Therapy

Volumn 24, Issue 5, 2017, Pages 263-264

  Baruteau, J ^a,b,c   Waddington, S N ^c,d   Alexander, I E ^e,f   Gissen, P ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e SYDNEY CHILDREN'S HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR;

CROSS REACTION; GENE EXPRESSION; GENE THERAPY; HUMAN; LIVER; LIVER CELL; METABOLIC ACTIVITY ASSAY; NONHUMAN; NOTE; PRIORITY JOURNAL; RELIABILITY; TRANSGENE; ANIMAL; ANIMAL MODEL; DEPENDOPARVOVIRUS; DRUG THERAPY; GENE VECTOR; GENETICS; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIVER; MODELS, ANIMAL;

EID: 85009371748     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2016.90     Document Type: Note

References (18)

1. Dolgin E. Early clinical data raise the bar for hemophilia gene therapies. Nat Biotechnol 2016; 34: 999-1001.
2. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
3. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994-2004.
4. D'Avola D, Lopez-Franco E, Sangro B, Paneda A, Grossios N, Gil-Farina I et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol 2016; 65: 776-783.
5. Paneda A, Lopez-Franco E, Kaeppel C, Unzu C, Gil-Royo AG, D'Avola D et al. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther 2013; 24: 1007-1017.
6. Montenegro-Miranda PS, Paneda A, ten Bloemendaal L, Duijst S, de Waart DR, Gonzalez-Aseguinolaza G et al. Adeno-associated viral vector serotype 5 poorly transduces liver in rat models. PLoS One 2013; 8: e82597.
7. Wang L, Bell P, Somanathan S, Wang Q, He Z, Yu H et al. Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol Ther 2015; 23: 1877-1887.
8. Unzu C, Sampedro A, Mauleon I, Alegre M, Beattie SG, de Salamanca RE et al. Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol Ther 2011; 19: 243-250.
9. Nathwani AC, Gray JT, McIntosh J, Ng CY, Zhou J, Spence Y et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 2007; 109: 1414-1421.
10. Mattar CN, Nathwani AC, Waddington SN, Dighe N, Kaeppel C, Nowrouzi A et al. Stable human FIX expression after 0.9G intrauterine gene transfer of selfcomplementary adeno-associated viral vector 5 and 8 in macaques. Mol Ther 2011; 19: 1950-1960.
11. Vercauteren K, Hoffman BE, Zolotukhin I, Keeler GD, Xiao JW, Basner-Tschakarjan E et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther 2016; 24: 1042-1049.
12. Inagaki K, Piao C, Kotchey NM, Wu X, Nakai H. Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver. J Virol 2008; 82: 9513-9524.
13. Cunningham SC, Kok CY, Dane AP, Carpenter K, Kizana E, Kuchel PW et al. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery. Mol Ther 2011; 19: 854-859.
14. Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites 2014; 4: 977-1006.
15. London IM. The use of stable isotopes in biological and medical research. J Clin Invest 1949; 28(6 Pt 1): 1255-1270.
16. Cunningham SC, Spinoulas A, Carpenter KH, Wilcken B, Kuchel PW, Alexander IE. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol Ther 2009; 17: 1340-1346.
17. Hu C, Tai DS, Park H, Cantero G, Chan E, Yudkoff M et al. Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAVbased gene therapy. Gene Ther 2015; 22: 111-115.
18. Opladen T, Lindner M, Das AM, Marquardt T, Khan A, Emre SH et al. In vivo monitoring of urea cycle activity with (13)C-acetate as a tracer of ureagenesis. Mol Gene Metab 2016; 117: 19-26.